C1346 字2:12新闻报道美国腔发布于 2026年7月17日 · 更新于 2026年7月17日

完整音频预览

0:00

British pharmaceutical giant GSK announced on Friday that it would discontinue development of camlipixant, an experimental chronic cough treatment it acquired through a two-billion-dollar deal three years ago.

英国制药巨头葛兰素史克于周五宣布，将停止研发 camlipixant，这是一款该公司于三年前通过一笔二十亿美元的交易中所收购的实验性慢性咳嗽治疗药物。

The drug discontinuation followed mixed Phase 3 data, with the company conceding that the medication had failed to meet nearly all primary endpoints in two late-stage clinical trials.

在第三期临床试验数据呈现好坏参半的结果后，该药物随即宣告终止研发，该公司也承认这款药物在两项晚期临床试验中，几乎未能达到所有的主要疗效指标。

GSK emphasized that the limited efficacy demonstrated was unlikely to transform patient care in any meaningful way.

葛兰素史克强调，所显示出的有限疗效不太可能以任何有意义的方式改变患者护理。

GSK had originally gained access to camlipixant upon acquiring Bellus Health, a move that came despite the drug having initially failed in a Phase 2 trial.

葛兰素史克最初是在收购 Bellus Health 时获得 camlipixant 的使用权，尽管该药物最初在第二期临床试验中失败，但仍进行了这项收购行动。

A subsequent mid-stage study had delivered more promising results, showing a statistically significant reduction in cough frequency.

随后进行的一项中阶段研究取得了更具前景的结果，显示出在咳嗽频率上具有统计学意义的显著降低。

The lower dose of fifty milligrams taken twice daily, which had proved effective in that earlier study, was the highest dose evaluated in the Phase 3 clinical trials.

在先前的研究中被证实有效的每日两次、每次五十毫克的较低剂量，是第三期临床试验中所评估的最高剂量。

The termination effectively closes what had been a blockbuster opportunity for GSK, which had hoped to incorporate camlipixant into its existing portfolio of respiratory drugs, including asthma and chronic obstructive pulmonary disease treatments such as Trelegy and Anoro.

这项终止实际上关闭了葛兰素史克原本视为畅销药物的绝佳机会，该公司曾希望将 camlipixant 纳入其现有的呼吸道药物产品组合中，其中包括哮喘以及慢性阻塞性肺病治疗药物，例如 Trelegy 和 Anoro。

Nevertheless, the company confirmed that it is continuing Phase 2 trials of camlipixant in patients with irritable bowel syndrome, suggesting the drug may yet find a viable therapeutic application.

然而，该公司证实，目前正持续进行 camlipixant 在大肠激躁症患者身上的第二期临床试验，这表明该药物仍有可能找到可行的治疗应用。

Camlipixant is now the third drug in the P2X3 antagonist class to fail in pharma development, following similar setbacks encountered by Bayer and Merck and Company.

camlipixant 目前已成为 P2X3 拮抗剂类别中第三款在制药研发中宣告失败的药物，此前拜耳和默沙东也遭遇过类似的挫折。

#10

Merck had reportedly spent more than five hundred million dollars to gain control of its own candidate in this class.

据报道，默沙东已花费超过五亿美元，以取得其在该类别中自身候选药物的控制权。

#11

Industry analysts have cautioned that these repeated failures raise fundamental questions about whether P2X3 antagonists can deliver sufficient clinical benefit for chronic cough patients.

业界分析师警告，这些接连的失败对 P2X3 拮抗剂是否能為慢性咳嗽患者提供足够的临床疗效提出了根本性的质疑。

#12

The setback does, however, clear away a competitive threat to Trevi Therapeutics, which is advancing a fundamentally different type of treatment for chronic cough.

然而，这次挫折确实为 Trevi Therapeutics 扫除了一个竞争威胁，该公司目前正在开发一种本质上完全不同的慢性咳嗽治疗方法。

#13

Had camlipixant succeeded, it would have posed a significant challenge to Trevi's market prospects.

若 camlipixant 取得成功，它本会对 Trevi 的市场前景构成重大挑战。

#14

Investors will undoubtedly be scrutinizing GSK's broader pipeline strategy in the coming weeks, particularly given the substantial financial commitment the company made to secure this now-abandoned asset.

投资者无疑将在未来几周内仔细审视葛兰素史克的更广泛产品线策略，特别是考虑到该公司为了获取这个如今已被放弃的资产而做出的重大财务承诺。

GSK shelves cough drug acquired in $2B deal

完整音频预览

学习模式

学习内容

单词表 (8 个单词)

片语表 (3 个片语)

推荐课程

学员评价

单词表 (8 个单词)

片语表 (3 个片语)

完整音频预览

学习模式

学习内容

单词表 (8 个单词)

片语表 (3 个片语)

推荐课程

What is immunotherapy and how does it treat cancer and other conditions?什么是免疫疗法？它如何治疗癌症和其他疾病？

Big Pharma's Next Billion-Dollar Bet Is Magic Mushrooms, MDMA And LSD. Could Psychedelic Drugs...迷幻藥邁入主流醫療市場

Traffic, mobiles, music … let’s turn the volume down隱形的健康殺手：都市噪音污染危機

Meta's Zuckerberg says US should not block Chinese AI models, FT reports扎克伯格警告：限制中國人工智慧或損害美國競爭力

学员评价

单词表 (8 个单词)

片语表 (3 个片语)